Position paper of Italian rheumatologists on the use of biosimilar drugs

Fabiola Atzeni, Marco Sebastiani, Cristian Ricci, Antonella Celano, Elisa Gremese, Florenzo Iannone, Pier Luigi Meroni, Paola Minghetti, Piercarlo Sarzi-Puttini, Gianfranco Ferraccioli, Giovanni Lapadula

Risultato della ricerca: Contributo in rivistaArticolo in rivista

17 Citazioni (Scopus)


The recent availability of biosimilars as a result of the expiry of the patents of first-generation biotechnological drugs may theoretically reduce the direct costs of such treatments, making their use accessible to a larger number of patients. However, the currently available clinical data refer to a relatively small number of patients, and do not provide sufficient information concerning long-term efficacy and safety or the frequency of rare adverse events. Given the importance of the introduction of biosimilar drugs and the limitations of our current knowledge of their efficacy and safety profiles, we believe it is mandatory to draw up a position paper for Italian Rheumatologists. Moreover, in order to guarantee their safety, it is mandatory to indicate behavioural rules for the involved specialists and competent authorities, and perform ad hoc clinical trials and appropriate drug surveillance.
Lingua originaleEnglish
pagine (da-a)1-4
Numero di pagine4
RivistaClinical and Experimental Rheumatology
Stato di pubblicazionePubblicato - 2015


  • Antirheumatic Agents
  • Biosimilar Pharmaceuticals
  • Drug Substitution
  • Drug and Narcotic Control
  • Informed Consent
  • Patents as Topic
  • Patient Safety
  • Rheumatic Diseases
  • Rheumatology
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome


Entra nei temi di ricerca di 'Position paper of Italian rheumatologists on the use of biosimilar drugs'. Insieme formano una fingerprint unica.

Cita questo